Research involving two osimertinib‐resistant cell lines strongly suggests that the critical mechanism by which sensitive EGFR‐mutant NSCLC cells become resistant to osimertinib‐mediated apoptosis induction occurs via an inability of osimertinib to modulate B‐cell lymphoma 2‐like 11 (Bim) and myeloid cell leukemia sequence 1 (Mcl‐1) levels (Shi et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.